INOZYME PHARMA, INC. Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
INOZYME PHARMA, INC. had Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount of $14.90 million as of 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized · last filed 2025-03-10
- 2024-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $14.90M.
- 2023-12-31: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $11.60M.
- 2023-09-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $15.00M.
- 2023-06-30: Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $13.00K.
| Period end | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount |
|---|---|
| 2024-12-31 | $14.90M 10-K · filed 2025-03-10 |
| 2023-12-31 | $11.60M 10-K · filed 2024-03-12 |
| 2023-09-30 | $15.00M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $13.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $9.30M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $11.80M 10-K · filed 2023-03-22 |
| 2022-09-30 | $14.90M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $16.70M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $19.50M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $19.30M 10-K · filed 2022-03-15 |
| 2021-09-30 | $20.00M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $21.20M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $23.80M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $13.90K 10-K · filed 2021-03-25 |
| 2020-09-30 | $12.60M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $2.50M 10-Q · filed 2020-09-03 |